# Conitec drug incorporation decisions in Brazil

> Live situation record from CLSTR: https://clstr.news/situations/conitec-drug-incorporation-decisions-in-brazil
> Updated: 2026-08-20T19:13:42.000Z. Sources: 3. Developments: 2.

Brazil’s National Commission for the Incorporation of Technologies in the Unified Health System (Conitec) has made decisions regarding treatment options for Paroxysmal Nocturnal Hemoglobinuria (PNH).

During an extraordinary meeting on August 19, 2026, Conitec recommended the incorporation of iptacopana, an oral medication for patients with persistent symptoms despite using a C5 inhibitor. This decision provides the SUS with its first second-line treatment option for PNH.

Conversely, the Commission recommended the exclusion of ravulizumabe from the SUS, citing changes to the price parameter of the comparator drug. Conitec also decided against the incorporation of crovalimabe or pegcetacoplana.

## Timeline

### 2026-08-20: Conitec recommends iptacopana for PNH treatment in Brazil

Brazil's Conitec has recommended incorporating the oral drug iptacopana as a second-line treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) in the SUS, while recommending the exclusion of ravulizumabe.

3 sources. https://clstr.news/cluster/conitec-recommends-iptacopana-for-pnh-treatment-in-brazil

### 2026-08-10: Conitec evaluates including sotatercept in Brazil's SUS

Brazil's Conitec has opened a public consultation to consider adding the drug sotatercept to the SUS for treating adult patients with pulmonary arterial hypertension.

13 sources. https://clstr.news/cluster/conitec-evaluates-inclusion-of-sotatercept-in-brazils-public-health-system

---
Cite as: Conitec drug incorporation decisions in Brazil. CLSTR, https://clstr.news/situations/conitec-drug-incorporation-decisions-in-brazil